Arbios Systems, a medical device and cell-therapy company, has sold all its rights and interest in its bioartificial liver system, HepatAssist, to HepaLife Technologies, a biotechnology company developing proprietary cell-based medical technologies.

Arbios Systems has received the FDA approval for an investigational device exemption to begin the pivotal clinical trial for Sepet, the company's extracorporeal liver assist device for blood purification of acutely ill patients suffering from chronic liver disease.

Arbios Systems has received conditional approval from the FDA to begin the pivotal clinical trial for Sepet, an extracorporeal or outside the body artificial liver assist device for blood purification of chronically ill patients suffering from acute liver failure.